PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26021F0164Ponatinib 15mg TAB — Millennium Pharmaceuticals, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Apr 4, 2021 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

260-Network Contract Office 20 (36C260)

Awarding office

Millennium Pharmaceuticals, Inc

Recipient

Apr 4, 2021

PoP end

$23K

Obligated

$116K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Federal

Contract number36C26021F0164

Also listed as36C260-21-F-0164

Also listed as36F79718D0586-36C26021F0164

Agency260-Network Contract Office 20 (36C260)

Awarding office260-Network Contract Office 20 (36C260)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentMillennium Pharmaceuticals, Inc

CAGE3FLV7

UEIENNFDLWFC6L1

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79718D0586

Place of performanceCAMBRIDGE MA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startJan 5, 2021

PoP end (current)Apr 4, 2021

Obligated$23K

Current value$116K

Potential value$116K

PONATINIB 15MG TAB is a federal award for 260-Network Contract Office 20 (36C260) held by Millennium Pharmaceuticals, Inc. Estimated value $116K ($23K obligated). Current period of performance ends Apr 4, 2021. Last award drew 1 bidder. Place of performance: CAMBRIDGE MA.

Recompete timing

Public

● Past PoP end (2005 days ago)

Current PoP ended Apr 4, 2021 (2005 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Bonuses end Sept 30

Want the durability read on 36C26021F0164? One Pursuit Analysis, $500, inside 48 business hours.

48 business hours
$500
Credits toward the Pack

Buy one Pursuit Analysis — $500

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26021F0164?

36C26021F0164 (Ponatinib 15mg TAB) is a 260-Network Contract Office 20 (36C260) award with a potential value of $116K, currently held by Millennium Pharmaceuticals, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C260-21-F-0164?

36C260-21-F-0164 is the dashed form of PIID 36C26021F0164 (Ponatinib 15mg TAB), held by Millennium Pharmaceuticals, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26021F0164?

260-Network Contract Office 20 (36C260) awarded 36C26021F0164 to Millennium Pharmaceuticals, Inc (potential $116K).

Who is the incumbent on 36C26021F0164?

Millennium Pharmaceuticals, Inc is the incumbent. The current period of performance ends Apr 4, 2021.

When does Millennium Pharmaceuticals, Inc’s 36C26021F0164 come up for recompete?

SCOUT tracks a period-of-performance end of Apr 4, 2021. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 36C26021F0164? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Oct 29, 2021 · refreshed monthly